Perrigo (PRGO) Swung To A Loss In Q3, Is It Still Undervalued?

Perrigo earnings jolt investor focus

Perrigo (NYSE:PRGO) has moved back into the spotlight after reporting third quarter results that showed lower sales, a shift to a net loss, and a sharply wider loss for the first nine months of 2026.

Perrigo’s earnings release has landed after a strong run in the share price, with a 30 day share price return of 9.63% and a 90 day gain of 26.24%. However, the 5 year total shareholder return of a 52.76% decline highlights how recent momentum contrasts sharply with a much weaker longer term record.

Scan how Perrigo’s recent swing from profit to loss compares with other consumer health players by zeroing in on our hand picked list of solid balance sheet and fundamentals (25 results).

Perrigo has a long established consumer health franchise, yet the shares have just surged after a quarter that swung from profit to loss. Does that recent move leave the business fairly valued or still mispriced?

Most Popular Narrative: 12% Undervalued

The most followed narrative on Perrigo pegs fair value at $18 a share, above the last close at $15.83. This frames the recent rally against a still discounted starting point.

Increasing consumer cost-consciousness is driving stronger adoption of store-brand (private label) OTC products, with Perrigo reporting accelerated unit and volume share gains. This structural shift is expanding Perrigo's addressable market and supports enduring top-line revenue growth.

See why 13 investors see Perrigo as 12% undervalued.

Result: Fair Value of $18 (UNDERVALUED)

Still, this bullish Perrigo narrative could crack if weak category demand persists or if private label pricing pressure squeezes already thin profit expectations.

Find out about the key risks to this Perrigo narrative.

Next Steps

Mixed signals around Perrigo can make the story feel messy, which is exactly why fresh eyes on the numbers matter right now. For a more complete view of the full set of risks and potential upsides, review the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Perrigo?

If Perrigo has sharpened your focus, do not stop here. You owe it to your portfolio to keep hunting for opportunities that fit your risk and return goals.

• Target resilient compounding potential by tracking companies that combine earnings strength with cleaner balance sheets through the list of solid balance sheet and fundamentals (25 results).
• Spot potential value gaps by scanning for companies that pair quality fundamentals with prices that may lag business strength using the 34 high quality undervalued stocks.
• Build a steadier income stream by reviewing businesses that offer stronger yield profiles and consistent shareholder payouts through the 5 dividend fortresses.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com